HealthLynked (HLYK) AI Stock Analysis

• Market Cap: $6.51M
• Dividend Yield: N/A
• Average Volume (3M): 2.50K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.49
• Revenue Growth: -28.51%
• EPS Growth: 38.80%
• Country: US
• Employees: 20
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): N/A
• Shares Outstanding: 2,866,104
• 10 Day Avg. Volume: 3,502
• 30 Day Avg. Volume: 2,501
• PEG Ratio: >-0.01
• Price to Book (P/B): -1.93
• Price to Sales (P/S): 2.00
• P/FCF Ratio: -1.72
• Enterprise Value/Market Cap: 1.99
• Enterprise Value/Revenue: 5.44
• Enterprise Value/Gross Profit: 5.56
• Enterprise Value/Ebitda: -6.16
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 45 Neutral
• Price Target: $4.00 ▲(173.97% Upside)

The score is held down primarily by very weak financial performance (shrinking revenue, widening losses, negative free cash flow, and negative equity). Technical momentum is positive and provides some support, but valuation is impaired by ongoing losses and the absence of dividend yield data.

Positive Factors

Recurring revenue model

A subscription and transaction-based revenue mix creates predictable, recurring cash inflows and diversified monetization. Over 2-6 months this supports customer retention and scalable unit economics, enabling the firm to leverage its platform as adoption grows despite near-term headwinds.

Relatively high gross margins

Sustained high gross margins suggest the core platform and services have favorable unit economics. If the company stabilizes revenue and controls operating costs, these margins provide a structural pathway to profitability and reinvestment in product and sales capabilities over the medium term.

Strengthened leadership and governance

Adding an experienced COO and two board members with insurance, risk management, and capital markets expertise is a structural improvement. It can materially improve execution, capital project financing, and strategic partnerships, enhancing financing access and long-term expansion prospects.

Negative Factors

Sharp revenue decline

A multi-year revenue contraction erodes scale, reduces leverage over fixed costs, and signals challenges in customer acquisition or retention. Persisting declines constrain reinvestment, weaken competitive positioning, and make reaching sustainable profitability more difficult without structural strategy changes.

Negative shareholders' equity

Material negative equity indicates liabilities exceed assets, impairing balance sheet flexibility. This condition raises solvency concerns, limits access to traditional debt or equity financing, and increases dependence on dilutive or costly funding, threatening long-term operational stability.

Persistent negative free cash flow

Consistently negative operating and free cash flow forces reliance on external financing to fund operations. That dependence can dilute shareholders, restrict investment in product and go-to-market activities, and heighten execution risk if capital access tightens over the medium term.

HealthLynked Business Overview & Revenue Model

Company Description

HealthLynked (HLYK) is a healthcare technology company focused on creating a patient-centric platform that enhances the delivery and management of healthcare services. The company operates primarily in the health information technology sector, providing a suite of solutions aimed at improving patient engagement, accessibility of health records, and facilitating communication between patients and healthcare providers. Core products include a network that enables patients to manage their medical history and connect with healthcare professionals, as well as tools for healthcare providers to streamline operations and improve patient care.

How the Company Makes Money

HealthLynked generates revenue through various channels, including subscription fees from healthcare providers who utilize its platform for managing patient data and communication. The company also earns money from transaction fees associated with services offered within its network, such as telehealth consultations and appointment scheduling. Additionally, partnerships with healthcare organizations and payers can lead to revenue-sharing arrangements that contribute to its earnings. By focusing on enhancing the efficiency of healthcare delivery and patient engagement, HealthLynked capitalizes on the growing demand for digital health solutions.

HealthLynked Financial Statement Overview

Summary

Financials are severely weak: revenues fell sharply (2021 to 2024), losses widened materially in 2024, free cash flow remains negative, and stockholders’ equity turned deeply negative—raising financial distress and potential solvency concerns.

Income Statement

The income statement shows declining revenues from $9,197,992 in 2021 to $3,008,361 in 2024, indicating significant revenue contraction. Gross profit margins remained relatively high, but the company experienced substantial net losses, increasing from -$1,012,203 in 2023 to -$6,131,479 in 2024. The EBIT and EBITDA margins are also negative, reflecting ongoing operational challenges and negative earnings before interest and taxes.

Balance Sheet

The balance sheet reveals a negative stockholders' equity of -$3,129,209 in 2024, down from $804,730 in 2023, highlighting financial instability. The debt-to-equity ratio is effectively unmeasurable due to negative equity, suggesting high leverage. The equity ratio is negative, indicating liabilities exceed assets, signaling potential insolvency risks.

Cash Flow

Cash flow analysis shows consistently negative free cash flow, with -$3,494,122 in 2024. Operating cash flow is negative, indicating the company is not generating sufficient cash from operations to cover its expenses. There is a slight improvement in financing cash flow, suggesting reliance on external financing to sustain operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.37M	3.01M	5.72M	5.86M	9.20M	6.13M
Gross Profit	2.32M	2.91M	2.35M	5.40M	6.18M	4.97M
EBITDA	-2.10M	-4.36M	-2.75M	-7.05M	-9.85M	-4.73M
Net Income	-3.83M	-6.13M	-1.01M	-8.82M	-10.41M	-6.15M
Balance Sheet
Total Assets	1.76M	2.22M	4.28M	4.58M	10.69M	8.03M
Cash, Cash Equivalents and Short-Term Investments	10.91K	76.24K	247.22K	61.89K	3.29M	162.18K
Total Debt	6.08M	997.85K	1.97M	1.28M	978.19K	3.04M
Total Liabilities	7.20M	5.35M	3.48M	4.27M	3.49M	6.68M
Stockholders Equity	-5.43M	-3.13M	804.73K	314.45K	7.20M	1.35M
Cash Flow
Free Cash Flow	-1.59M	-3.50M	-4.15M	-4.39M	-3.79M	-2.14M
Operating Cash Flow	-1.59M	-3.49M	-4.14M	-4.36M	-3.77M	-2.12M
Investing Cash Flow	425.00K	422.40K	3.51M	-544.75K	-341.36K	1.81M
Financing Cash Flow	1.17M	2.90M	824.09K	1.68M	7.24M	356.80K

HealthLynked Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.46
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HLYK, the sentiment is Negative. The current price of 1.46 is below the 20-day moving average (MA) of 3.79, below the 50-day MA of 2.48, and below the 200-day MA of 2.28, indicating a bearish trend. The MACD of 0.33 indicates Positive momentum. The RSI at 39.89 is Neutral, neither overbought nor oversold. The STOCH value of 13.07 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HLYK.

HealthLynked Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

HealthLynked Corporate Events

HealthLynked Appoints New COO to Boost Strategy

On December 8, 2025, HealthLynked Corp. appointed Duncan McGillivray as Chief Operating Officer, bringing over 30 years of leadership experience in healthcare, technology, and capital markets. His appointment is expected to enhance the company’s strategic initiatives, particularly in capital project financing. Additionally, HealthLynked expanded its Board of Directors by appointing Chris G. Pulos and Jason Bishara, effective December 1, 2025. These appointments aim to strengthen the company’s governance and support its national expansion and potential Nasdaq listing. Pulos and Bishara bring extensive expertise in insurance, healthcare risk management, and financial services, aligning with HealthLynked’s strategy to improve healthcare outcomes through AI-powered solutions.

The most recent analyst rating on (HLYK) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on HealthLynked stock, see the HLYK Stock Forecast page.